Mary Looby @MaryLoobyPharmD

Critical Care / Anticoagulation Clinical Pharmacy Specialist | CVICU | Inova Heart and Vascular Institute Falls Church, VA Joined February 2012

Tweets

194
Followers

100
Following

368
Likes

1K

Mary Looby @MaryLoobyPharmD

3 years ago

Will we soon have safer antithrombotic options for LVAD patients? #ARIES says yes to aspirin withdrawal #DOACLVAD investigates apixaban in #HM3

Matt Dimond @Matt_Dimond1

3 years ago

Withdrawal of aspirin is safe in #LVAD patients, how about apixaban instead of warfarin? Introducing the DOAC LVAD Study—design paper online NOW @JCardFail 👇 #ARIES #DOAC #LVAD @PalakShahMD @MaryLoobyPharmD @coconnormd @IHVInews doi.org/10.1016/j.card…

2 30 69 12K 6

0 3 6 763 0

View Details

Palak Shah @PalakShahMD

3 years ago

@Matt_Dimond1 @JCardFail @MaryLoobyPharmD @coconnormd @IHVInews @ShashankSinhaMD @mpsotka @iyadisseh @JamieLWKennedy Major reduction in bleeding with #ARIES trial in #LVAD pts. Now let’s improve #QOL and healthcare burden with #DOAC therapy. Read the DOAC LVAD study design paper. @preventfailure @manreetkanwar @TomCascinoMD @rcogswell_umn @KeyurBShahRIC

0 8 24 5K 0

View Details

Mary Looby @MaryLoobyPharmD

4 years ago

A program and an RPD so good it makes me want to go back and do a PGY2 all over again !!

Interested in an ID PGY2? Join us at one of our virtual info sessions on either 11/30 or 12/14 to learn more about our ASHP accredited program at @YNHH in New Haven, CT. Register at: surveymonkey.com/r/FGJ2D2Q or via the QR code.#IDTwitter #PharmRes @omattacycline @ruxyID @abripenem

0 10 13 0 0

0 0 1 0 0

View Details

Mary Looby @MaryLoobyPharmD

4 years ago

Big shoes to fill but great opportunity!

Steph Witek @StephWitek

4 years ago

💊✨JOB ALERT ✨💊 Searching for an abdominal transplant pharmacist at Inova Fairfax in Northern VA! 💊 >120 kidney/panc txps last year 💊 Plenty of precepting Job link: tinyurl.com/2s4f9aab DMs are open for questions! @accpimtrprn @AST_TXPHARMCOP #TxPharm #TwitteRx

0 3 9 0 0

0 0 5 0 0

View Details

Mary Looby @MaryLoobyPharmD

5 years ago

One of the most exciting things I’ve been a part of in my career. 🤩 Cannot wait to share what we learn @IHVInews @PalakShahMD #DOACLVAD

Inova Schar Heart and Vascular @ISHVnews

5 years ago

Thrilled to announce launch of the first @IHVInews FDA IND trial, DOAC LVAD, to evaluate safety of apixaban in patients with LVADs. Congratulations @PalakShahMD, Mary Looby and the AHF & VAD Research Teams @bradbumm clinicaltrials.gov/ct2/show/NCT04…

2 22 94 0 3

0 3 13 0 0

View Details

Mary Looby @MaryLoobyPharmD

5 years ago

Inova’s PGY2 Critical Care open house this Tuesday! Sign up to learn more🗓

IFMCpharmres @IFMCPharmres

5 years ago

Just posted a photo @ Inova Fairfax Hospital instagram.com/p/CWyY1QLFW0S/…

1 1 3 0 0

0 2 7 0 0

View Details

IFMCpharmres @IFMCPharmres

5 years ago

Just posted a photo @ Inova Fairfax Hospital instagram.com/p/CWyY1QLFW0S/…

1 1 3 0 0

View Details

Mary Looby @MaryLoobyPharmD

5 years ago

Not to mention andexanet at 5-10x⬆️ cost vs others… with no known advantage.

UK ICU Pharmacy @UKCritCarePharm

5 years ago

🔑💭: How do DOAC reversal agents compare? A meta-analysis from Gomez-Outes et al analyzed 4-PCC, idarucizumab & andexanet for reversal of severe bleeding associated with DOACs. 60 studies & 4735 pts: 🚫difference in mortality ↔️hemostatic efficacy ⬆️VTE with andexanet

2 31 121 0 28

0 0 2 0 0

View Details

des_linden @des_linden

5 years ago

“It takes 10 years to become an overnight success.” - marathoners “Hold my beer.” - Molly Seidel #TeamUSA

89 2K 10K 0 26

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

@InovaHealthAPPs @cockrambobby @InovaHealth @InovaCNE @DrMotew @InovaHealthToni We are so lucky to have @cockrambobby !!

0 0 0 0 0

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

@bamardis @ISHLT @bamardis would love to learn more and collaborate on something larger. Are you doing this inpatient or outpatient? We launched our pharmacist-run outpatient IV iron clinic for HF patients about 6 months ago.

0 0 1 0 0

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

Way to go @IanBHollis 👏🏻👏🏻. Moving in the right direction where less is more.

Palak Shah @PalakShahMD

6 years ago

Happening now #ISHLT2021, UNC 90-pt study, no ASA in #LVAD patients from implant reduces hemocompatibility related adverse events. 6-fold higher risk of bleeding with ASA, no increase in stroke. @bradbumm @NirUrielMD @preventfailure @manreetkanwar @rcogswell_umn @tonkhueMdPhd

3 21 97 0 7

0 0 3 0 0

View Details

Palak Shah @PalakShahMD

6 years ago

3 21 97 0 7

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

Great resource for learners of all disciplines.

Bug Pharmacist 💊🧫 Tim Gauthier @IDstewardship

6 years ago

📄🤓👾💊🦠🔬📖 Updated my antibiotic cheat sheet to being a “bugs & drugs cheat sheet” 📲 LearnAntibiotics.com 💬 Any suggestions for additional updates are 😃 welcomed. #IDtwitter #TwitteRx

25 258 870 0 300

0 0 4 0 0

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

@acweyand Seems that way. I would like more information before seeing such a strong recommendation to move to 3rd, 4th line agents for a disease where UFH and LMWH are well-established in improving outcomes. 🤞 more info soon!

1 0 0 0 0

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

In the NEJM article they state low dose heparin (LMWH) DECREASED platelet activation and that PF4 activation was independent of heparin. I’m puzzled by why the authors concluded heparin can’t be used. No SRA to corroborate a functional heparin rxn.

Shematologist, MD @acweyand

6 years ago

I’m addition to a similar clinical picture, patients w/VITT post @AstraZeneca demonstrated PF4 heparin antibodies. It is extremely important to differentiate this from other thrombosis as heparin should NOT be used in these patients. 5/x

1 7 65 0 2

3 0 3 0 0

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

Upstream Xa inhibition preventing thrombin generation proving to be 🔑... dabig failed in VADs and mechanical valves (RE-ALIGN). More potential for Xa inhibitors based on case series in VADs and ongoing PROACT Xa (apix w/ On-X valve). Can we ⬇️ GIB in VADs with this approach?🤞🤞

Palak Shah @PalakShahMD

6 years ago

@YasMoayedi @FilioBillia @sarsch79 @WilcoxHeart @SusanJosephMD @ShelleyZieroth @KevinShahMD @docbhardwaj @JonGrinsteinMD @preventfailure @manreetkanwar @rcogswell_umn The German study used dabigatran which is a direct thrombin inhibitor and showed harm. Apixaban works through a different pathway (Xa inhibitor), which is more important in VADs. @bradbumm ahajournals.org/doi/10.1161/CI…

1 0 5 0 0

0 1 8 0 2

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

Yessss. Felt like we were in a tough spot with RED VELVT signaling we need to use VKA for LVT. Great to have a controlled trial to clarify/correct this. 👏🏻

Yehia Saleh @YehiaSaleh_MD

6 years ago

Happy to share the results of No-LVT @JACCJournals -79 patients with left ventricular thrombi were randomized to rivaroxaban vs warfarin -Rivaroxaban was non-inferior and had faster thrombus resolution in comparison to warfarin. @EchofirstB jacc.org/doi/10.1016/j.…

26 297 777 0 35

0 0 4 0 0

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

Ahhh how did I leave off my old friend and favorite HF cardiologist @PalakShahMD ... newly connected in the twitterverse

0 0 0 0 0

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

Not to mention the most supportive team a pharmacist could ask for @mpsotka @ShashankSinhaMD @cmrosner @FinniganApril @jennasmithrx @AirInBags @ErikOsborn77

1 0 5 0 0

View Details

Mary Looby @MaryLoobyPharmD

6 years ago

@InovaCareers @IHVInews @InovaHealth is looking for cardiology trained pharmacists to join our established cardiac critical pharmacy team! We've got it all.... cardiogenic shock, HF, durable and temp MCS, PH, txp, and expanding pharmacist-run clinics for endless opportunities.